Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 90 | 5,124 | 48% |
| 2020 | 80 | 4,782 | 50% |
| 2021 | 83 | 5,074 | 52% |
| 2022 | 96 | 5,902 | 53% |
| 2023 | 106 | 6,793 | 55% |
| 2024 | 119 | 8,499 | 56% |
| 2025 from claims | – | 10,531 9,665–11,142 | 56% |
| 2026 forecast | – | 11,613 10,218–13,401 | 56% |
| 2027 forecast | – | 12,735 10,887–15,177 | 56% |
| 2028 forecast | – | 13,965 11,653–17,100 | 56% |
| 2029 forecast | – | 15,314 12,508–19,205 | 57% |
| 2030 forecast | – | 16,792 13,452–21,518 | 57% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 33% of the cases CMS names in California; 54 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% inpatient hospital, 74% hospital outpatient, 1% surgery center, 1% office.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~11,600 | ~2,800 | ~8,700 | ~90 | ~95 |
| 2027 · ~12,700 | ~3,000 | ~9,500 | ~100 | ~110 |
| 2028 · ~14,000 | ~3,300 | ~10,400 | ~110 | ~120 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 38 | 3,079+16%/yr | +16%/yr | 4.2 | 0% | 5,590 in 2030+10%/yr |
| Washington | 31 | 1,779+2.1%/yr | +2.1%/yr | 2.3 | 0% | 2,570 in 2030+6.3%/yr |
| Colorado | 18 | 1,328+5.9%/yr | +5.9%/yr | 2.8 | 0% | 2,020 in 2030+7.2%/yr |
| Oregon | 10 | 796+5.6%/yr | +5.6%/yr | 1.9 | 0% | 1,500 in 2030+11%/yr |
| Nevada | 11 | 545+13%/yr | +13%/yr | 1.9 | 0% | 870 in 2030+8.2%/yr |
| Utah | 6 | 444+15%/yr | +15%/yr | 2.1 | 0% | 960 in 2030+14%/yr |
| Idaho | 5 | 286+3%/yr | +3%/yr | 1.4 | 0% | 650 in 2030+15%/yr |
| Montana | 5 | 277+1.2%/yr | +1.2%/yr | 1.5 | 0% | 310 in 2030+1.7%/yr |
| Hawaii | 6 | 241+24%/yr | +24%/yr | 1.9 | 0% | 590 in 2030+16%/yr |
| New Mexico | 4 | 210+8.1%/yr | +8.1%/yr | 0.9 | 0% | 570 in 2030+18%/yr |
| Alaska | 2 | 179+25%/yr | +25%/yr | 1.5 | 0% | 660 in 2030+24%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 1,451 | 361,322+0.6%/yr | +0.6%/yr | 112.01.1× | 55% | 413,200 in 2030+2.3%/yr |
| ERCP & endoscopic ultrasound | 165 | 12,633+0.7%/yr | +0.7%/yr | 3.91.3× | 1% | 15,600 in 2030+3.6%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Capsovision leads with 52% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 25 companies reported engagement with California’s surgeons worth $1.7M in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.